Pacira Pharmaceuticals Inc.
Patent owner in reexamination·1 ex parte reexams
Pacira Pharmaceuticals Inc.'s patents have been the subject of 1 USPTO ex parte reexamination. Its patents are most often challenged by Argentum Pharmaceuticals LLC. ExamPat indexes the full prosecution record for each proceeding, including office-action grounds, certificate outcomes, and downstream PTAB and Federal Circuit decisions.
Filings by year
Top requesters
Outcome track record
How reexams of this owner's patents resolve: claims confirmed, amended, mixed, or fully canceled.
- Certificate outcome split across every bucket
- Claim-survival rate
Defense metrics
Claim-survival rate, average pendency, and the open/closed split across every reexam of this owner's patents.
- Survival rate of closed proceedings
- Average pendency in months
Challengers & examiners
Which requesters most often challenge this owner's patents, and which examiners decide them.
- Top requesters
- Most frequent examiners
Recent reexaminations (1)
| Control # | Filed | Patent | Title | Requester | Status |
|---|---|---|---|---|---|
| 90/019,692 | Oct 3, 2024 | 11,033,495 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | Argentum Pharmaceuticals LLC | Closed |
See the full reexam picture for Pacira Pharmaceuticals Inc.
Certificate outcomes, pendency, and the parties and examiners behind these cases. Free to sign up.